Susquehanna International Group
UNCY icon

Susquehanna International Group’s Unicycive Therapeutics UNCY Stock Holding History

Susquehanna International Group’s Portfolio UNCY Stock Details UNCY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$1.31M Buy
199,219
+174,288
+699% +$1.14M ﹤0.01% 7208
2025
Q4 		$144K Buy
+24,931
New +$133K ﹤0.01% 11205

Other funds holding UNCY

VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
OCA
Octagon Capital Advisors New York $904M AUM 737.04% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
GPP
Great Point Partners Greenwich, Connecticut $435M AUM 318.81% 1-Year Est. Return
LGM
Logos Global Management San Francisco, California $2B AUM 444.09% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
IHAM
Integral Health Asset Management New York $2.09B AUM 112.84% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Susquehanna International Group's UNCY Position: Q1 2026 in Review

Susquehanna International Group increased its Unicycive Therapeutics (UNCY) stake by 699% in Q1 2026, buying an estimated $1.14M and bringing the position to 199,219 shares worth $1.31M. The position accounts for ﹤0.01% of the portfolio, ranked #7208.

Susquehanna International Group first reported a position in UNCY in Q4 2025 and has held it in 2 quarters since. 51 funds tracked by Wall St. Rank hold UNCY as of Q1 2026.

  • Susquehanna International Group held 199,219 shares of Unicycive Therapeutics worth $1.31M as of Q1 2026.
  • Susquehanna International Group bought 174,288 Unicycive Therapeutics shares in Q1 2026, an estimated $1.14M.
  • Unicycive Therapeutics made up ﹤0.01% of Susquehanna International Group's portfolio in Q1 2026, its #7208 holding.
  • Susquehanna International Group first reported a position in Unicycive Therapeutics in Q4 2025 and has held it in 2 quarters since.
  • 51 funds tracked by Wall St. Rank held Unicycive Therapeutics as of Q1 2026.

Based on Susquehanna International Group's 13F filing for Q1 2026, filed 15 May 2026.